Clinical trial
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the…
NCT00061932 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00061932 |
|---|---|
| Title | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach |
| Official title | A Phase II Study of PS-341 Alone or in Combination With Irinotecan in Patients With Adenocarcinoma of the Gastroesophageal Junction (GEJ) or Stomach |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer |
| Intervention type | Drug |
| Interventions | bortezomib, irinotecan |
| Enrollment | 41 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Nov 1, 2013 |
| First posted | Jun 6, 2003 |
| Last update posted | Feb 2, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: